Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran

Mohammadreza Amirsadri, Elahe Torkpour


Background and purpose: Several studies have shown the effectiveness of screening programs in decreasing the costs and disutility of type-2 diabetes and related complications. As there is a growth in the incidence of type-2 diabetes amongst the Iranian population, the cost-effectiveness of performing type-2 diabetes screening tests in community pharmacies of Iran was evaluated in this study from the payer’s perspective. The target population consisted of two hypothetical cohorts of 1000 people 40 years of age without a prior diagnosis of diabetes, for the intervention (screening test) and no-screening groups.

Experimental approach: A Markov model was developed to evaluate the cost-effectiveness and cost-utility of a type-2 diabetes screening test in community pharmacies in Iran. A 30-year time horizon was considered in the model. Three screening programs with 5-year intervals were considered for the intervention group. The evaluated outcomes were quality-adjusted life-years (QALYs) for cost-utility-analysis and life-years-gained (LYG) for cost-effectiveness-analysis. To examine the robustness of the results, one-way and probabilistic-sensitivity analyses were applied to the model.

Findings/Results: The screening test represented both more effects and higher costs. The incremental effects in the base-case scenario (no-discounting) were estimated to be 0.017 and 0.0004 (approximately 0) for QALYs and LYG, respectively. The incremental cost was estimated to be 2.87 USD/patient. The estimated incremental-cost-effectiveness ratio was 164.77 USD/QALY.

Conclusion and implications: This study indicated that screening for type-2 diabetes in community pharmacies of Iran could be considered highly cost-effective, as it meets the WHO criteria of the annual GDP per capita ($2757 in 2020).


Cost-effectiveness; Cost-utility; Markov-model; Screening; Type-2 diabetes.

Full Text:



International Diabetes Federation. Diabetes Atlas Update 2021. Available at: http: //

Esteghamati A, Etemad K, Koohpayehzadeh J, Abbasi M, Meysamie A, Noshad S, et al. Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005-2011. Diabetes Res Clin Pract. 2014;103(2):319-327.DOI: 10.1016/j.diabres.2013.12.034.

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Rev Endocrinol. 2018;14(2):88-98. DOI: 10.1038/nrendo.2017.151.

Javanbakht M, Mashayekhi A, Baradaran HR, Haghdoost A, Afshin A. Projection of diabetes population size and associated economic burden through 2030 in Iran: evidence from micro-simulation Markov model and Bayesian meta-analysis. PLoS One. 2015;10(7):e0132505,1-17. DOI: 10.1371/journal.pone.0132505.

Moradpour F, Rezaei S, Piroozi B, Moradi G, Moradi Y, Piri N, et al. Prevalence of prediabetes, diabetes, diabetes awareness, treatment, and its socioeconomic inequality in west of Iran. Sci Rep. 2022:12:17892,1-11. DOI: 10.1038/s41598-022-22779-9.

Farshchi A, Esteghamati A, Akbari Sari A, Kebriaeezadeh A, Abdollahi M, Abedin Dorkoosh F, et al. The cost of diabetes chronic complications among Iranian people with type-2 diabetes mellitus. J Diabetes Metab Disord. 2014;13(1):42,1-14. DOI: 10.1186/2251-6581-13-42.

Amirsadri M, Sedighi MJ. Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran. Res Pharm Sci. 2017; 12(2):144-153. DOI: 10.4103/1735-5362.202453.

Edejer TTT, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making choices in health: WHO guide to cost-effectiveness analysis‎. World Health Organization (WHO);2003. Available at:

Abdoli G. Estimation of social discount rate for Iran. Eco Res Rev. 2009;9(34):135-156.

Amirsadri M, Rahimi F, Khajepour A. Cost of illness of multiple sclerosis in Isfahan, Iran, from a social perspective: a comparison of the human-capital and friction-cost methods. Value Health Reg Issues. 2022;30:26-30. DOI: 10.1016/j.vhri.2021.10.006.

Preedy VR, Watson RR, editors. Handbook of disease burdens and quality of life measures. Springer; New York; 2010. pp. 4355

ISBN: 978-0-387-78665-0

Bingefors K, Pashos CL, Smith MD, Berger ML, Hedblom EC, Torrance GW, editors. Health care cost, quality, and outcomes: ISPOR book of terms. 1st ed. ISPOR; ISPOR, Lawrenceville, New Jersey; 2003. pp. 195-205

Chen TH, Yen MF, Tung THA. computer simulation model for cost-effectiveness analysis of mass screening for type-2 diabetes mellitus. Diabetes Res Clin Pract. 2001;54 (Suppl 1):S37-S42. DOI: 10.1016/s0168-8227(01)00307-2.

Bayazidi Y, Davari M. The estimation of the imposed economic burden due to inadequate medical care in patients suffering from type-2 diabetes in Tehran. Tamine-Ejtemaies Social Security Quarterly. 2020;15(4):121-131.

The Central Bank of Iran (CBI). Exchange Rates. Available at: Accessed 1ST March 2021.

Schaufler TM, Wolff M. Cost effectiveness of preventive screening programmes for type-2 diabetes mellitus in Germany. Appl Health Econ Health Policy. 2010;8(3):191-202. DOI: 10.2165/11532880-000000000-00000.

The cost-effectiveness of screening for type-2 diabetes. CDC diabetes cost-effectiveness study group, centers for disease control and prevention. JAMA. 1998; 280(20):1757-1763. PMID: 9842951.

Shah A D, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type-2 diabetes and incidence of cardiovascular diseases: a cohort study in 1•9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105-113. DOI: 10.1016/S2213-8587(14)70219-0.

Roper N, Bilous R, Connolly V. Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study. Diabetes Care. 2002;25(1):43-48. DOI: 10.2337/DIACARE.25.1.43.

Janghorbani M, Amini M, Ghanbari H, Safaiee H. Incidence of and risk factors for diabetic retinopathy in Isfahan, Iran. Ophthalmic Epidemiol. 2003;10(2):81-95. DOI: 10.1076/opep.

Toscano CM, Zhuo X, Imai K, Duncan BB, Polanczyk CA, Zhang P, et al. Cost-effectiveness of a national population-based screening program for type-2 diabetes: the Brazil experience. Diabetol Metab Syndr. 2015;7,95,1-11. DOI: 10.1186/s13098-015-0090-8.

Amini M, Parvaresh E. Prevalence of macro- and microvascular complications among patients with type-2 diabetes in Iran: A systematic review. Diabetes Res Clin Pract. 2009;83(1):18-25. DOI: 10.1016/j.diabres.2008.10.010.

Noshad S, Afarideh M, Heidari B, Mechanick JI, Esteghamati A. Diabetes care in Iran: where we stand and where we are headed. Ann Glob Health. 2015;81(6):839-850. DOI: 10.1016/j.aogh.2015.10.003.

Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: the Isfahan cohort study. Arch Iran Med. 2013;16(3):138-144. PMID: 23432164.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(14):1-160, iii-iv. DOI: 10.3310/hta11140.

The World Bank. GDP per capita. Available at: https : // CD?locations=IR. Accessed 10 Sep 2021.

Wright D, Little R, Turner D, Thornley T, et al. Diabetes screening through community pharmacies in England: a cost-effectiveness study. Pharmacy (Basel). 2019;7(1):30,1-12. DOI: 10.3390/pharmacy7010030.

Shono A, Kondo M, Shoshi S, Okubo R, Yahagi N. Cost-effectiveness of a new opportunistic screening strategy for walk-in fingertip HbA1c testing at community pharmacies in Japan. Diabetes Care. 2018;41(6):1218-1226. DOI: 10.2337/dc17-1307.


  • There are currently no refbacks.

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.